Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders.
Sabbadin C, Beggiao F, Keiko Vedolin C, Orlando G, Ragazzi E, Ceccato F, Barbot M, Bordin L, Donà G, Andrisani A, Belloni Fortina A, Scaroni C, Armanini D.
Sabbadin C, et al. Among authors: armanini d.
Endocr Metab Immune Disord Drug Targets. 2023;23(2):188-195. doi: 10.2174/1871530322666220509051746.
Endocr Metab Immune Disord Drug Targets. 2023.
PMID: 35532249